23andMe, once valued at $6 billion following its 2021 IPO, has experienced a dramatic decline, with its stock plummeting by 98% and its market cap approaching nearly zero. The company, known for its personal genetic testing kits, is now facing a dire financial situation, with concerns that it may run out of cash by 2025. CEO Anne Wojcicki is currently working on strategies to turn the company around. Rolfe Winkler of The Wall Street Journal has provided an in-depth report on the company's fall from grace, which has been described as a significant drop from a once highly-regarded startup to a position of being virtually worthless.
23andMe's Fall From $6 Billion To Nearly $0 https://t.co/pjYHHB2DvS
"23andMe’s Fall From $6 Billion to Nearly $0" https://t.co/xWtwTiNA3d This is a really interesting article. It's a shame that their really cool product may lack a "business case." Wojcicki (about whom I knew nothing) seems decent enough for a big-ego Silicon Valley-type, lol.
$ME 23andMe’s Fall From $6 Billion to Nearly $0 - WSJ https://t.co/z3GN9JQww3
23andMe's stock, which hit a $6B valuation after a 2021 IPO, has crashed 98% and 23andMe may run out of cash by 2025, as CEO Anne Wojcicki plots a turnaround (@rolfewinkler / Wall Street Journal) https://t.co/AIcVsVDbhh https://t.co/35QKEAppLX
23andMe was once one of the hottest startups. Now it’s virtually worthless. https://t.co/Zqcxf4ZvEH
What happened 23andme? By @RolfeWinkler From $6 billion market cap to nearly zero. Very well reported and very well told. @WSJ https://t.co/bt7zwto9he